How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
- PMID: 39455547
- DOI: 10.1007/s40265-024-02106-4
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Abstract
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates for the treatment of PTSD given their effects on multiple memory systems. Most PTSD and psychedelic research has investigated memory with fear conditioning and extinction. While fruitful, conditioning and extinction provide a limited model of the complexity of PTSD and phenomenology of psychedelics, thereby limiting the refinement of therapies. In this review, we discuss abnormalities in fear conditioning and extinction in PTSD and review 25 studies testing psychedelics on these forms of memory. Perhaps the most reliable effect is that the acute effects of psychedelics can enhance extinction learning, which is impaired in PTSD. However, the post-acute effects may also enhance extinction learning, and the acute effects can also enhance fear conditioning. We then discuss abnormalities in episodic and semantic memory in PTSD and review current knowledge on how psychedelics impact these memory systems. Although PTSD and psychedelics acutely impair the formation of hippocampal-dependent episodic memories, psychedelics may acutely enhance cortical-dependent learning of semantic memories that could facilitate the integration of trauma memories and disrupt maladaptive beliefs. More research is needed on the acute effects of psychedelics on episodic memory consolidation, retrieval, and reconsolidation and post-acute effects of psychedelics on all phases of episodic memory. We conclude by discussing how targeting multiple memory mechanisms could improve upon the current psychedelic therapy paradigm for PTSD, thereby necessitating a greater emphasis on assessing diverse measures of memory in translational PTSD and psychedelic research.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Funding: JED receives research support from the National Institutes of Health (NIH), National Science Foundation (NSF), and US-Israel Binational Science Foundation. JMC receives research support from NIH and Texas Child Mental Health Care Consortium. GAF receives research support from the Brain and Behavior Research Foundation, NIH (with grant numbers R61MH132722, R33MH108753, R01MH119132, R01AA030740, K23MH114023, TCMHCC, R01MH117293, R01AA029090, R01MH122387, R01MH125886, R01AA030038, R01MH129694 ), and the One Mind–Baszucki Brain Research Fund. CBN receives research support from NIH and Texas Child Mental Health Care Consortium. These funding sources had no role in the writing of this manuscript other than supporting salaries. Conflict of interest: Manoj K. Doss is an advisor to VCENNA. Gregory A. Fonzo has served as a consultant for SynapseBio AI, and is a stockholder in Alto Neuroscience. Charles B. Nemeroff has served as a consultant for AbbVie, ANeuroTech (division of Anima BV), BioXcel Therapeutics, Clexio, EMA Wellness, EmbarkNeuro, Engrail Therapeutics, Intra-Cellular Therapies, GoodCap Pharmaceuticals, Magstim, Ninnion Therapeutics, Pasithea Therapeutics, Sage, Senseye, Signant Health, Silo Pharma, SynapseBio, and Relmada Therapeutics; has served on scientific advisory boards for ANeuroTech, the Anxiety and Depression Association of America (ADAA), the Brain and Behavior Research Foundation, Heading Health, the Laureate Institute for Brain Research, Pasithea Therapeutics, Sage, Signant Health, and Skyland Trail, and on the Boards of Directors for ADAA, Gratitude America, and Lucy Scientific Discovery; is a stockholder in Corcept Therapeutics, EMA Wellness, Galen Mental Health, Relmada Therapeutics; and is named on patents related to psychiatric treatment. None of these groups had any role in the writing of this manuscript. AnnaMarie DeMarco, Joseph E. Dunsmoor, and Josh M. Cisler have no conflicts of interest to declare that may be relevant to the contents of this article. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent to publish: The journal has our consent to publish. Availability of data and material: Not applicable. Code availability: Not applicable. Author contributions: MKD conceived of the ideas behind this manuscript and wrote the original manuscript. AdM, JED, JMC, GAF, and CBN conceived of the ideas behind this manuscript and edited the manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.
Similar articles
-
Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.Psychopharmacology (Berl). 2018 Feb;235(2):433-445. doi: 10.1007/s00213-017-4793-4. Epub 2017 Nov 25. Psychopharmacology (Berl). 2018. PMID: 29178010 Review.
-
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents.Neurosci Biobehav Rev. 2024 Dec;167:105899. doi: 10.1016/j.neubiorev.2024.105899. Epub 2024 Sep 19. Neurosci Biobehav Rev. 2024. PMID: 39305969 Review.
-
Understanding posttraumatic stress disorder through fear conditioning, extinction and reconsolidation.Neurosci Biobehav Rev. 2016 Dec;71:48-57. doi: 10.1016/j.neubiorev.2016.08.023. Epub 2016 Aug 31. Neurosci Biobehav Rev. 2016. PMID: 27590828 Review.
-
Revisiting propranolol and PTSD: Memory erasure or extinction enhancement?Neurobiol Learn Mem. 2016 Apr;130:26-33. doi: 10.1016/j.nlm.2016.01.009. Epub 2016 Jan 22. Neurobiol Learn Mem. 2016. PMID: 26808441 Free PMC article. Review.
-
The role of endocannabinoids in consolidation, retrieval, reconsolidation, and extinction of fear memory.Pharmacol Rep. 2021 Aug;73(4):984-1003. doi: 10.1007/s43440-021-00246-y. Epub 2021 May 6. Pharmacol Rep. 2021. PMID: 33954935 Review.
Cited by
-
Methylone promotes neurite outgrowth and has long-lasting effects on fear extinction learning.Neuropsychopharmacology. 2025 Aug 23. doi: 10.1038/s41386-025-02206-z. Online ahead of print. Neuropsychopharmacology. 2025. PMID: 40849539
References
-
- Brewin CR, Holmes EA. Psychological theories of posttraumatic stress disorder. Clin Psychol Rev. 2003;23:339–76. https://doi.org/10.1016/S0272-7358(03)00033-3 . - DOI - PubMed
-
- Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017;376:2459–69. https://doi.org/10.1056/NEJMra1612499 . - DOI - PubMed
-
- Stein DJ, McLaughlin KA, Koenen KC, Atwoli L, Friedman MJ, Hill ED, et al. DSM-5 and ICD-11 definitions of posttraumatic stress disorder: investigating “narrow” and “broad” approaches. Depress Anxiety. 2014;31:494–505. https://doi.org/10.1002/da.22279 . - DOI - PubMed - PMC
-
- Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. AJP. 2005;162:214–27. https://doi.org/10.1176/appi.ajp.162.2.214 . - DOI
-
- Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2015;206:93–100. https://doi.org/10.1192/bjp.bp.114.148551 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01MH122387/MH/NIMH NIH HHS/United States
- R33MH108753/MH/NIMH NIH HHS/United States
- TCMHCC/Texas Child Mental Health Care Consortium
- K23MH114023/MH/NIMH NIH HHS/United States
- R01MH129694/MH/NIMH NIH HHS/United States
- R01MH119132/MH/NIMH NIH HHS/United States
- R01AA029090/AA/NIAAA NIH HHS/United States
- R01 MH122387/MH/NIMH NIH HHS/United States
- R01AA030038/AA/NIAAA NIH HHS/United States
- 1844792/National Science Foundation
- AWD00003047/United States - Israel Binational Science Foundation
- R61MH132722/MH/NIMH NIH HHS/United States
- R01AA030740/AA/NIAAA NIH HHS/United States
- R01MH125886/MH/NIMH NIH HHS/United States
- R01MH117293/MH/NIMH NIH HHS/United States
- R01MH122387/MH/NIMH NIH HHS/United States
- R61MH132722/MH/NIMH NIH HHS/United States
- R33MH108753/MH/NIMH NIH HHS/United States
- R01MH119132/MH/NIMH NIH HHS/United States
- K23MH114023/MH/NIMH NIH HHS/United States
- R01MH117293/MH/NIMH NIH HHS/United States
- R01MH122387/MH/NIMH NIH HHS/United States
- R01MH125886/MH/NIMH NIH HHS/United States
- R01MH129694/MH/NIMH NIH HHS/United States
- R01AA030740/AA/NIAAA NIH HHS/United States
- R01AA029090/AA/NIAAA NIH HHS/United States
- R01AA030038/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical